This 2004 narrative review synthesizes BMP biology from initial discovery through clinical translation. It covers receptor architecture, Smad signal transduction, four levels of negative regulation, disease-causing mutations, and preclinical/clinical evidence for rhBMP-2 in bone repair and spinal fusion. The paper frames why BMP pathway components are relevant far beyond bone grafting.
When you use rhBMP-2 for spinal fusion or fracture non-union, you are activating a pathway under tight negative control by noggin, sclerostin, Smad6, Tob, and Smurf1. Variable clinical responses to BMP-2 — including cases of inadequate fusion or ectopic bone. Make more sense once you understand that local concentrations of these regulators differ by patient, tissue bed, and delivery conditions.
When you see a patient with progressive heterotopic ossification and congenital great toe deformity, think FOP and ectopic BMP-4 overexpression. Not a post-traumatic or iatrogenic process. When a young patient presents with proximal interphalangeal joint ankylosis, carpal/tarsal fusions, and conductive deafness, heterozygous noggin mutation (proximal symphalangism or multiple synostoses syndrome) belongs on your differential.
Sclerostin, covered here as a BMP antagonist produced by osteocytes, became the target of romosozumab. An anti-sclerostin monoclonal antibody now used for osteoporosis. Making this review a direct precursor to a clinically relevant drug class. The Smurf1 and sclerostin data in this paper explain why osteocyte signaling is now a central focus of bone anabolic drug development.
This 2004 narrative review synthesizes BMP biology from initial discovery through clinical translation. It covers receptor architecture, Smad signal transduction, four levels of negative regulation, disease-causing mutations, and preclinical/clinical evidence for rhBMP-2 in bone repair and spinal fusion. The paper frames why BMP pathway components are relevant far beyond bone grafting.
When you use rhBMP-2 for spinal fusion or fracture non-union, you are activating a pathway under tight negative control by noggin, sclerostin, Smad6, Tob, and Smurf1. Variable clinical responses to BMP-2 — including cases of inadequate fusion or ectopic bone. Make more sense once you understand that local concentrations of these regulators differ by patient, tissue bed, and delivery conditions.
When you see a patient with progressive heterotopic ossification and congenital great toe deformity, think FOP and ectopic BMP-4 overexpression. Not a post-traumatic or iatrogenic process. When a young patient presents with proximal interphalangeal joint ankylosis, carpal/tarsal fusions, and conductive deafness, heterozygous noggin mutation (proximal symphalangism or multiple synostoses syndrome) belongs on your differential.
Sclerostin, covered here as a BMP antagonist produced by osteocytes, became the target of romosozumab. An anti-sclerostin monoclonal antibody now used for osteoporosis. Making this review a direct precursor to a clinically relevant drug class. The Smurf1 and sclerostin data in this paper explain why osteocyte signaling is now a central focus of bone anabolic drug development.